For example, POLE-mutation and MSI-H/dMMR endometrial carcinomas are associated with high tumor mutation burden (TMB) and significantly increase immune cell infiltration, which are excellent indications for immune checkpoint blockade strategies, particularly anti-PD-1/PD-L1 therapy [10,11]. The gene discussed is CD274; the disease is neoplasm.